Moderna, Inc. participates in Barclays 26th Annual Global Healthcare Conference

Moderna, Inc. recently participated in the Barclays 26th Annual Global Healthcare Conference, where Lavina Talukdar, the Senior Vice President and head of Investor Relations, represented the company. During the conference, Moderna outlined its projections for COVID-19 revenue in 2024, with a total expected revenue of $4 billion. This figure includes $1 billion from COVID-19 Advanced Purchase Agreements, $2 billion from U.S. revenue, and $1 billion from international COVID-19 sales and sales related to Respiratory Syncytial Virus (RSV). Moderna also discussed the EU tender process for potentially supplying up to 36 million doses of COVID-19 vaccines annually for four years, with pricing anticipated to be lower than that in the U.S. at a range of $30 to $35 per dose. The company aims to boost vaccination rates in the U.S. through public health initiatives and is actively engaged in conversations with other countries, such as Japan, for potential vaccine sales. Moderna also shared its RSV data and noted that it expects approval for its RSV vaccine in time for the June ACIP meeting, allowing it to be available in the market by fall 2024. The frequency of RSV vaccinations will be determined by the CDC based on data collection.

Participation in Barclays 26th Annual Global Healthcare Conference

Moderna, Inc. (MRNA) had the privilege of participating in the esteemed Barclays 26th Annual Global Healthcare Conference. Representing the company at the conference was Lavina Talukdar, Senior Vice President and Head of Investor Relations. This event provided an invaluable platform for Moderna to showcase its groundbreaking work in the healthcare industry and share its vision for the future.

COVID-19 Revenue Guidance for 2024

During the conference, Moderna provided valuable insights into its revenue projections for the year 2024, with a total revenue of $4 billion. This significant figure encompasses multiple revenue streams, including $1 billion generated from COVID-19 Advanced Purchase Agreements (APAs). Additionally, $2 billion is expected to be derived from U.S. revenue, while another $1 billion will be generated from international COVID-19 sales and Respiratory Syncytial Virus (RSV) sales.

EU Tender Process for COVID-19 Vaccines

Another key topic discussed at the conference was Moderna’s involvement in the EU tender process for COVID-19 vaccines. The company reiterated its commitment to providing a reliable supply of vaccines to address the ongoing pandemic. As part of this process, Moderna has the potential to supply up to 36 million doses annually for four years, ensuring a steady and ample supply for European countries.

Pricing for EU Market

In terms of pricing strategies, Moderna indicated that the EU market can expect lower pricing compared to the U.S. market. The company envisions a potential pricing range of $30 to $35 per dose, offering a more affordable option for European countries to procure the much-needed COVID-19 vaccines. This commitment to accessible pricing demonstrates Moderna’s dedication to global health.

Higher Vaccination Rates in the U.S.

Moderna has set a clear objective of achieving higher vaccination rates in the United States, and this was a key focus area in the discussions at the conference. In order to achieve this goal, the company has emphasized the importance of public health initiatives. By actively engaging with public health organizations and implementing targeted campaigns, Moderna aims to ensure that a larger proportion of the U.S. population receives the COVID-19 vaccine, contributing to herd immunity and protecting public health.

Data Collection for Improved Estimates

As part of its continuous improvement efforts, Moderna is actively collecting data to enhance its estimates of return reserves. This data-driven approach allows the company to make more accurate projections regarding its revenue. Moderna is optimistic about reaching approximately $2 billion in U.S. revenue this year, showcasing the favorable trajectory of its business operations.

Engagement with Other Countries for Vaccine Sales

Moderna recognizes the global demand for COVID-19 vaccines and has been engaging in active conversations with various countries, including Japan. These discussions aim to explore potential vaccine sales and partnerships that will enable the effective distribution of Moderna’s vaccines. By expanding its reach to countries beyond the U.S., Moderna can play a vital role in the worldwide effort to combat the COVID-19 pandemic.

RSV Data Comparison

Modernahas been actively involved in the research and development of a Respiratory Syncytial Virus (RSV) vaccine. During the conference, the company presented its RSV data and compared it to data from other competitors in the market. Notably, Moderna’s RSV vaccine demonstrated similar neutralizing antibody titers, highlighting the promising potential of the company’s RSV vaccine candidate.

Approval and Availability of RSV Vaccine

Moderna expressed optimism regarding the approval of its RSV vaccine in time for the June ACIP meeting. This milestone will be crucial in advancing the market availability of the RSV vaccine, with the company aiming to make it accessible by fall 2024. The approval of the RSV vaccine will provide immense benefits, potentially preventing severe respiratory illnesses in high-risk populations, such as infants and older adults.

Frequency of RSV Vaccinations

The frequency of RSV vaccinations will ultimately be determined by the Centers for Disease Control and Prevention (CDC) based on comprehensive data collection. Moderna, along with other stakeholders, will collaborate with the CDC to assess the effectiveness and necessity of RSV vaccinations over time. This collaborative approach ensures that the administration of RSV vaccinations aligns with the latest scientific evidence and the evolving needs of public health.

In conclusion, Moderna’s participation in the Barclays 26th Annual Global Healthcare Conference showcased the company’s comprehensive understanding of the healthcare landscape and its commitment to addressing the ongoing COVID-19 pandemic. Through effective revenue guidance, active engagement with global markets, and groundbreaking research and development efforts, Moderna continues to make significant contributions to public health initiatives worldwide. With promising data from its RSV vaccine candidate and a focus on improving vaccination rates, Moderna is poised to make a lasting impact in the healthcare industry and shape the future of preventive medicine.